BlueRock Therapeutics
-
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Gene-editing firms sign on to statement of ethical principles, with emphasis on germline editing
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
-
BioPharma, Events, Healthcare, Pharma, Startups, SYN
Meeting’s nearly fourfold attendance growth highlights cell, gene therapies’ rise
From bringing in a mere 350 scientists in an embattled field 12 years ago, this year’s Alliance for Regenerative Medicine Cell and Gene Meeting brought in more than 1,200.